FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug
NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.
BioCryst Pharmaceuticals: Owning Both Sides Of The HAE Preference Curve
BioCryst Pharmaceuticals (BCRX) is evolving into a dual-product hereditary angioedema (HAE) franchise, targeting both oral and injectable prophylactic preferences. BCRX's ORLADEYO profit engine supports pipeline funding; Q2 2026 revenue reached $218.3M, with strong gross margins and positive cash flow independent of licensing receipts. The navenibart acquisition positions BCRX to capture injectable-preferring HAE patients, leveraging existing commercial infrastructure for operating leverage and customer retention.
Haemonetics: Worth Speculating On This Recurring Medtech Plasma Model
Haemonetics is a medtech company that's increasingly generating more recurring revenues with plasma consumables. HAE also has MedSurg, which generates higher margins by selling technologies useful for cardiovascular procedures, for example. As such, these two segments give HAE a durable growth profile. And their recent agreement with CSL could expand on this potential.
Here's Why Haemonetics (HAE) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Haemonetics (HAE) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
HAE Stock Gains on Q1 Earnings & Revenue Beat, Fiscal '27 View Up
Haemonetics raises fiscal 2027 revenue guidance after Q1 earnings and sales beat, supported by Plasma growth and stronger cash generation.
Haemonetics (HAE) Reliance on International Sales: What Investors Need to Know
Examine Haemonetics' (HAE) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Haemonetics Q1 Earnings Call Highlights
Haemonetics NYSE: HAE reported a stronger start to fiscal 2027, with first-quarter revenue rising 6% year over year to $339 million and adjusted diluted earnings per share increasing 4% to $1.14. The company raised its full-year revenue outlook, citing broad-based growth across its MedSurg and apheresis businesses, while maintaining a disciplined stance on assumptions for the remainder of the year.
Haemonetics Corporation (HAE) Q1 2027 Earnings Call Transcript
Haemonetics Corporation (HAE) Q1 2027 Earnings Call Transcript
Haemonetics (HAE) Tops Q1 Earnings and Revenue Estimates
Haemonetics (HAE) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $1.07 per share. This compares to earnings of $1.1 per share a year ago.
Pharvaris: One Molecule Could Reshape Both Sides Of HAE Treatment
Pharvaris is positioned to build a vertically integrated HAE franchise with deucrictibant in both immediate-release (IR) and extended-release (XR) forms. PHVS's NDA for deucrictibant IR was accepted by the FDA, with a PDUFA date set for April 23, 2027, following strong Phase 3 RAPIDe-3 results. The CHAPTER-3 Phase 3 data for deucrictibant XR, expected Q3 2026, is the pivotal catalyst determining PHVS's potential as an end-to-end HAE platform.
Earnings Preview: Haemonetics (HAE) Q1 Earnings Expected to Decline
Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
